Clinical trial

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Psilocybin Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Design: INTERVENTIONAL · Status: RECRUITING · Phase: EARLY_PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2021-03-24

PhaseEARLY_PHASE1

Conditions

Depressive Symptomsunresolved

Depressionverified · MONDO: depressive disorder

Alzheimer Diseaseverified · MONDO: Alzheimer disease

Mild Cognitive Impairmentunresolved

Interventions

PsilocybinDRUG

Sponsors & collaborators

Johns Hopkins Universitylead sponsor

Council On Spiritual Practicescollaborator

Heffter Research Institutecollaborator

Mapped research locations

BaltimoreMaryland, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04123314 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.